Maria V. Mateos
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 22, 2026
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025).
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 08, 2026
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Journal: Nature medicine
Published: March 13, 2026
Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.
Journal: British journal of haematology
Published: March 09, 2026
Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.
Journal: Blood advances
Published: February 26, 2026
Study of post-translational modifications of p53 in multiple myeloma.
Journal: Blood cancer journal
Published: December 10, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2025
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 29, 2025
Last Updated: 09/26/2026